The present study focused on the 70% of gastric adenocarcinomas without amplification of ERBB2, FGFR2 or MET. Those with amplification and overexpression are predicted to be driven predominantly by signal via the tyrosine kinase receptor encoded by the amplified oncogene. The gene discussed is MET; the disease is gastric adenocarcinoma.